Arovella Therapeutics Limited Overview
Arovella Therapeutics is a Melbourne-based, ASX-listed micro-cap biotechnology company. It became a clinical-stage company in calendar 2026 and is developing allogeneic ("off-the-shelf") cell therapies based on invariant Natural Killer T (iNKT) cells. The platform was in-licensed from Imperial College London in 2021, when SUDA Pharmaceuticals pivoted away from oro-mucosal drug delivery. The lead asset, ALA-101, is a CD19-directed CAR-iNKT cell therapy. Its US FDA IND was accepted in January 2026, it received Australian ethics approval in June 2026, and its first clinical batch was released in September 2026. First-patient dosing in a Phase 1 trial at The Alfred, Melbourne, is now guided for late October 2026. Behind it sits ALA-105, a CLDN18.2-targeted CAR-iNKT product for gastric and pancreatic cancer armoured with IL-12-TM technology, plus an emerging autoimmune strategy built on CD19 B-cell depletion. Arovella is one of very few companies globally advancing CAR-iNKT cells. It has no product revenue, held A$14.4m of cash at 30 June 2026, and went through a shareholder-driven board overhaul in April–May 2026.
Company's own description (FY2026 Annual Report, paraphrased)
The FY2026 Annual Report gives the principal activity as development of the company's iNKT cell platform for treatment of cancer. Management describes the platform as a next-generation allogeneic cell therapy with potential uses in blood cancers, solid tumours and selected autoimmune diseases. iNKT cells are a naturally occurring immune subset. They can kill cancer cells directly, reshape the tumour microenvironment and recruit other immune effectors. When engineered with a chimeric antigen receptor (CAR), they keep these innate and adaptive functions and carry a low risk of graft-versus-host disease (GvHD). That low GvHD risk is what allows donor-derived, batch-manufactured dosing.
The stated strategy is a modular CAR-iNKT platform. A proprietary, semi-automated, patent-protected and FDA-cleared manufacturing process is combined with interchangeable CAR targets (CD19, CLDN18.2, others under evaluation), armouring modules (IL-12-TM) and complementary technologies (allo-defence, iNKT agonists). The aim is to create barriers to entry through know-how, IP and trade secrets. Management frames value creation through three workstreams: blood cancers (ALA-101), solid tumours (ALA-105 plus IL-12-TM) and autoimmune disease (ALA-101 repurposed for B-cell depletion).
Independent characterisation
Arovella is a single-segment, pre-revenue, platform-stage cell-therapy developer whose investment value rests almost entirely on one binary near-term readout: first-in-human safety, pharmacokinetic and B-cell-depletion data from ALA-101. It does not manufacture in-house at GMP scale. Clinical material is produced through a contract manufacturer (Cell Therapies Pty Ltd, CTPL, in Melbourne), and the trial is run through a contract research organisation (SAPRO). That makes it an asset-light "virtual-plus" biotech with a small in-house research laboratory (Jumar Bioincubator). Its IP rests mostly on in-licensed rights (Imperial College London for iNKT and IL-12-TM; SparX Group for the CLDN18.2 binder; MD Anderson for DKK1), plus its own manufacturing-process patents and know-how.
The legacy SUDA business, which reformulated established drugs as oral sprays on the OroMist platform, is no longer strategically relevant. ZolpiMist (zolpidem oral spray) licensing generated small, irregular revenues through FY2023 and none in FY2026.
Business model and revenue model
| Dimension | Current state (FY2026) | Intended future state |
|---|---|---|
| Product revenue | Nil | Commercial sales of approved CAR-iNKT products, or royalties from a partner |
| Service revenue | Nil | Not a stated strategy |
| Subscription revenue | Nil | Not applicable |
| Licensing revenue | Nil in FY2026. A$136,000 revenue from contracts with customers in FY2025 (nature not specified in sources reviewed; historically ZolpiMist-related licensing) | Out-licensing or regional partnering of ALA-101/ALA-105 (business development is an explicit board priority) |
| Non-operating income | R&D Tax Incentive A$3.50m; interest income A$0.80m (FY2026) | R&D Tax Incentive remains material while R&D is Australia-based |
Value-chain position
Arovella sits at the discovery-to-early-clinical development stage of the oncology and cell-therapy value chain:
Upstream: academic licensors (Imperial College London; MD Anderson; SparX Group); lentiviral vector and reagent suppliers (the company had SEK-denominated liabilities at 30 June 2026, implying at least one Swedish vendor); healthy-donor blood collection.
Midstream (Arovella's own role): CAR design and integration, process development (Jumar laboratory), regulatory filings (FDA IND; TGA CTN), clinical strategy and translational science.
Outsourced midstream: GMP manufacturing (CTPL), clinical operations (SAPRO), and trial sites (The Alfred, with other Australian and New Zealand sites in start-up).
Downstream (future): marketing approval, reimbursement and commercialisation, most likely through a large-pharma partner given the company's scale.
Customer types and end-markets
There are no paying customers today. The prospective end-markets are:
-
Haematological malignancies: relapsed/refractory CD19-positive non-Hodgkin lymphoma (NHL) and certain leukaemias. Payers would be hospital systems and national reimbursement bodies, with treating haematologists and cellular-therapy centres as prescribers.
-
Solid tumours: CLDN18.2-positive gastric and gastro-oesophageal junction cancer, and pancreatic cancer.
-
Autoimmune and neuro-immunological disease: B-cell-driven disorders. Stiff-person syndrome (SPS) is named explicitly as an example of high unmet need.
Strategy
Stated strategy (FY2026 Annual Report and Chair's letter, paraphrased)
- Build a leading next-generation allogeneic cell therapy company on a modular CAR-iNKT platform that combines the proprietary manufacturing process with new CAR targets, armouring and complementary technologies.
Generate first-in-human proof-of-concept: with ALA-101 and use it to de-risk the whole platform, including solid tumours and autoimmune indications.
Three value-creation workstreams: blood cancer (ALA-101), solid tumours (ALA-105 plus IL-12-TM), autoimmune (ALA-101 B-cell depletion).
- Board renewal focused on time to market, product development and business development, with the explicit aim of evaluating corporate and business-development initiatives to maximise shareholder value.
Continued in-licensing and assessment: of external technologies, including Baylor College of Medicine assets, additional CAR targets, allo-defence and agonists.
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| A$15m Phase 1 funding round | Feb–Mar 2025 | Replacement placement after the January 2025 investor default | Completed |
| Jumar in-house laboratory | FY2025–FY2026 | Research and process-development capability; A$0.42m PP&E additions in FY2025 | Operational |
| CRO appointment (SAPRO) | 29 Oct 2025 | Trial Pathway Partner for ALA-101 Phase 1 | Active |
| ALA-101 IND | Submitted 30 Dec 2025; accepted 29 Jan 2026 | FDA clearance of the manufacturing process and preclinical package | Complete |
| ANZ clinical start-up | Jan–Sep 2026 | TGA CTN; HREC approvals; The Alfred activation | Active |
| Clinical Advisory Board expansion | FY2026 | Prof. Cameron Turtle appointed; Dr Sam Fiorenza as Lead Investigator | Complete |
| Autoimmune strategy | FY2026 | Use Phase 1 B-cell-depletion data to support autoimmune expansion; SPS named as an example | Planning and translational stage |
| ALA-105 preclinical programme | FY2026 | CLDN18.2 CAR validated; IL-12-TM armouring data; in vivo gastric and pancreatic models | Ongoing |
| Scientific conference presence | Apr–May 2026 | Posters at AACR 2026 (San Diego, 20 Apr) and ISCT 2026 (Dublin, 7 May) | Complete |
| Board strategic review | From 4 May 2026 | Comprehensive review of technology, development strategy and growth opportunities; outcome presented in the 12 Aug 2026 webinar | Complete; formal written outcome not detailed in sources reviewed |
| Investor-relations reset | Aug–Sep 2026 | Investor webinar; sponsored analyst coverage (Prenzler, 16 Sep 2026) | Ongoing |
| ESG reporting | 17 Sep 2026 | 2026 ESG Report released to ASX | Released |
Cost programmes
No formal cost-reduction programme with targets has been announced. The shift to an outsourced CFO and company-secretarial model (Bio101) and a three-person board reduces fixed governance overhead.
Medium-term guidance and targets
| Item | Guidance | Source |
|---|---|---|
| First-patient dosing (ALA-101) | Late October 2026 (revised from September 2026) | 1 Oct 2026 filing |
| Preliminary clinical data | Early CY2027 | Corporate presentation / investor update summaries |
| Financial targets | None. No revenue, margin or cash-burn targets have been issued | — |
Products & Services
There are no marketed products in the current strategic portfolio. The catalogue below lists each programme individually.
ALA-101 — CD19-directed allogeneic CAR-iNKT cell therapy (lead)
| Attribute | Detail |
|---|---|
| Description | Healthy-donor-derived iNKT cells transduced with a lentivirus encoding a CD19-targeting CAR. The cells also keep their invariant T-cell receptor, which recognises glycolipid-loaded CD1d, an antigen found on several cancer types. This gives a dual-targeting mechanism (CAR plus iTCR) |
| Indications | Relapsed/refractory CD19+ non-Hodgkin lymphoma and certain leukaemia subtypes; potential expansion into B-cell-driven autoimmune disease (e.g. stiff-person syndrome) |
| Preclinical claims | Per the FY2026 Annual Report, ALA-101 outperformed conventional CAR-T cells against cell lines expressing both CD19 and CD1d, killed cancer cells rapidly and improved survival in mouse lymphoma and leukaemia models. Earlier Imperial data cited by Edison (2021) showed brain lymphoma eliminated in 13 of 18 CAR-iNKT-treated animals |
| Manufacturing | Donor blood collection, iNKT isolation, lentiviral transduction, expansion to billions of cells, then vialling and cryopreservation. The process is semi-automated, patent-protected and cleared by the FDA within the IND. Clinical batches are made by CTPL in Melbourne |
| Regulatory status | FDA IND accepted 29 Jan 2026; TGA CTN acknowledged; HREC approvals (The Alfred, Bellberry) June 2026 |
| Trial design | Phase 1 first-in-human, open-label, dose escalation (to establish the maximum tolerated dose) followed by dose expansion/backfill. A single dose is given. Endpoints cover safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy, plus measurement of CD19+ B-cell depletion |
| Sites | The Alfred, Melbourne (lead; activated 7 Sep 2026). Further Australian and New Zealand sites are in start-up. US sites are possible under the IND in future |
| Timeline | First clinical batch released 7 Sep 2026; first-patient dosing guided for late Oct 2026 (revised 1 Oct 2026 from September); preliminary data guided for early CY2027 (corporate presentation summary) |
| Licence source | Imperial College London (exclusive, global, oncology field) |
| Target customer | Haematology and cellular-therapy treatment centres |
| Pricing model | Not publicly disclosed (pre-commercial) |
| Launch year | Not applicable (Phase 1) |
ALA-105 — CLDN18.2-directed CAR-iNKT (solid tumours)
| Attribute | Detail |
|---|---|
| Description | CAR-iNKT cells targeting Claudin 18.2, a clinically validated tight-junction antigen expressed in gastric, gastro-oesophageal junction and pancreatic cancers |
| Origin | CLDN18.2 binder licensed from SparX Group under a collaboration dated 10 Oct 2023 |
| Armouring | Designed to incorporate IL-12-TM. FY2026 data indicated that IL-12-TM improved the activity and durability of CAR-iNKT cells in relevant solid-tumour models |
| Stage | Preclinical. CAR functionality confirmed, with potent in vitro killing of CLDN18.2+ cells (preclinical data announced April 2026). Gastric and pancreatic in vivo models established and efficacy studies started; process development has begun at Jumar using a scaled-down manufacturing model |
| Next steps | In vivo proof-of-concept with and without IL-12-TM, followed by IND-enabling activities (timing not guided) |
| Target customer | Oncology centres treating gastric and pancreatic cancer |
| Pricing model | — |
IL-12-TM armouring technology (enabling module)
| Attribute | Detail |
|---|---|
| Description | A membrane-tethered form of interleukin-12 expressed by engineered cells. It is designed to boost CAR-iNKT cell activity and persistence locally while limiting the systemic toxicity associated with free IL-12 |
| Source | Imperial College London (licence) |
| Use | To be incorporated into solid-tumour programmes, starting with ALA-105 |
ALA-104 — DKK1-directed CAR-iNKT (historic / deprioritised)
| Attribute | Detail |
|---|---|
| Description | CAR-iNKT targeting Dickkopf-1 (DKK1)-derived peptide presented on tumour cells, based on a monoclonal-antibody technology from MD Anderson |
| Licence terms | Global exclusive; undisclosed upfront and milestones; single-digit royalties (Edison, FY2022) |
| Current status | Absent from 2025–2026 company boilerplate and the FY2026 operating review. Status is not publicly disclosed and the programme appears deprioritised |
Pipeline-expansion and complementary technology work (FY2026)
| Workstream | Detail |
|---|---|
| Baylor College of Medicine assets | Continuing discussions on in-licensing assets. Contract manufacturer CTPL separately referred to Arovella technologies targeting neuroblastoma and hepatocellular carcinoma as potential future products. Terms are not disclosed and no deal is confirmed |
| iNKT agonist combination | Research collaboration evaluating an iNKT cell agonist with ALA-101 (counterparty not disclosed) |
| ALA-105 combination approaches | Research collaboration(s); counterparties not disclosed |
| Allo-defence technologies | Evaluation of approaches to protect allogeneic cells from host rejection (counterparties not disclosed) |
| Autoimmune translational work | Testing on samples from patients with autoimmune disease to prioritise indications (e.g. SPS) |
Legacy SUDA drug-delivery assets (non-core)
| Product | Description | Last known status |
|---|---|---|
| ZolpiMist | Oral spray of zolpidem tartrate for short-term insomnia (spray version of the drug marketed as Ambien/Stilnox). Rights held outside North America | TGA-approved (29 Jul 2020); licensed to STADA Australia (launched FY2022); approved in Chile; Teva licence for Brazil, Mexico and Chile (2017). No FY2026 revenue; current commercial status not publicly disclosed |
| OroMist platform | Oro-mucosal delivery technology for cheeks, gums, tongue or floor of mouth | Not an active strategic programme; status not publicly disclosed |
| Anagrelide oral spray | Oro-mucosal reformulation of anagrelide (oncology) | Not mentioned in FY2026 reporting; presumed discontinued (not publicly confirmed) |
Financial Narrative
All figures are in AUD millions unless otherwise stated. FY2022–FY2026 revenue, net loss, year-end share price and market capitalisation come from the audited five-year table in the FY2026 Remuneration Report. FY2025–FY2026 detail comes from the FY2026 audited statements. FY2024 cash and equity come from the opening balances in the FY2026 statements of cash flows and changes in equity. FY2022–FY2023 cash comes from the Kalkine aggregator and is corroborated for FY2022 by Edison (net cash A$6.1m).
Income statement
Derivation notes: EBITDA = net loss + D&A − interest income. Operating loss = net loss − interest income; it includes the R&D Tax Incentive, which Arovella classifies within other income. Gross profit is not reported; the company has no cost of sales.
Margins: Gross, operating, EBITDA and net margins are not meaningful because revenue is nil or negligible. In FY2025, for example, the net loss was about 55 times revenue. Revenue CAGR (FY2022–FY2026) is not meaningful because revenue fell to zero.
Commentary. The loss trajectory has improved in each of the three years since its FY2023 peak of A$10.18m: down 14.1% in FY2024, 14.1% in FY2025 and 7.9% in FY2026. The FY2026 improvement did not come from cost cutting. Research costs fell by A$0.65m (−9.9%) as preclinical ALA-101 work tapered and spending shifted into clinical start-up. Interest income doubled to A$0.80m on the higher average cash balance after the March 2025 raise. The R&D Tax Incentive rose 5.9% to A$3.50m. These gains were partly offset by a 25.8% rise in employee benefits (team expansion at Jumar, plus severance-type effects around the CEO transition) and an 18.6% rise in other expenses, which plausibly reflects governance, legal and board-transition costs from the April–May 2026 requisition events (not separately quantified by the company). Share-based payments fell 43% to A$0.48m, helped by option lapses following director and CEO departures. Former CEO Baker's options line shows a negative A$32,120 reversal.
The FY2027 cost base should rise once patients are dosed, because clinical-trial, manufacturing-release and CRO costs scale with enrolment. The company disclosed R&D commitments of about A$1.89m at 30 June 2026.
Balance sheet
Commentary. The balance sheet is simple: almost entirely cash, no debt, no capitalised intangibles (all licence and R&D costs are expensed), and modest plant and equipment, mostly the Jumar laboratory fit-out added in FY2025 (A$0.42m of additions). Equity has fallen to A$14.15m against A$121.3m of cumulative capital raised, so about A$108.6m of accumulated losses has been absorbed since 1999. Arovella also carries a net unrecognised deferred tax asset of A$23.4m, including A$20.6m relating to revenue losses. At the 30% rate this implies about A$68.7m of carried-forward revenue tax losses, subject to continuity-of-ownership and similar-business tests. This is a contingent value item that the market does not price.
Cash flow
Quarterly burn (Appendix 4C): Net operating outflows were A$2.5m in the December 2025 quarter, with R&D and staff at 90% of outflows and 7.6 quarters of funding estimated at the time. In the June 2026 quarter they were A$2.3m, with R&D and staff at 89%, and the quarter closed with A$14.4m of cash.
Runway assessment (analyst): Gross quarterly outflows have run at A$2.3–2.8m, and the annual R&D Tax Incentive refund of about A$3.5m arrives in a lump. Before trial-enrolment cost escalation, that implies roughly 5–7 quarters of runway from 30 June 2026, i.e. funding into late CY2027. Once dose escalation is under way, a capital raise in the next 6–12 months is highly probable. The likely timing is after initial ALA-101 safety or B-cell-depletion data, if the share price allows. Note: this is an analyst estimate, not company guidance. The company's FY2026 going-concern note says only that cash is sufficient for current requirements and that the directors are confident of accessing further funding when required.
Ratios
Notes: ROIC, net debt/EBITDA and interest coverage are not meaningful because EBITDA is negative and there is no debt or interest expense. The cash conversion cycle is not meaningful because there is no revenue or inventory. FY2025 ROA would require FY2024 total assets, which are not disclosed in the sources reviewed.
Trends, inflections and drivers
-
Funding-cycle dependence. Cash rises and falls with episodic placements: A$6.6m gross in FY2022, A$12.5m in March 2024 and A$15m in March 2025. The failed January 2025 placement, caused by a single investor's default, shows the fragility of micro-cap financing.
-
Loss stabilisation at about A$7m a year, helped by Australia's 43.5% refundable R&D Tax Incentive, which offsets roughly 35–40% of eligible spend each year.
-
Coming inflection: FY2027 should see a step-up in clinical costs. The FY2026 loss is therefore a floor for FY2027, not a run-rate.
-
Dilution: Weighted shares rose 9.5% in FY2026 (1,097.2m to 1,201.1m), mainly reflecting the full-year effect of the March 2025 placement and 18.98m option exercises.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / programmes |
|---|---|---|
iNKT cell therapy development (sole segment) | All R&D, clinical, manufacturing-development, corporate and residual legacy licensing activity | ALA-101 (CD19 CAR-iNKT); ALA-105 (CLDN18.2 CAR-iNKT ± IL-12-TM); IL-12-TM armouring; ALA-104 (DKK1 CAR-iNKT, historic); allo-defence and agonist collaborations; legacy ZolpiMist/OroMist rights |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue (AUD Mn) | 0.017 | 0.136 | 0 |
Segment pre-tax result (AUD Mn) | -8.746 | -7.509 | -6.916 |
Revenue YoY growth (%) | -95.8 | 700.0 | -100.0 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Group Structure
| Layer | Composition |
|---|---|
Board | Three non-executive directors: David Williams (Chair), Mark Diamond, Dr Michael Thurn |
Executive | Dr Nicole van der Weerden (Acting CEO); Lachie Mallia (CFO and Company Secretary, outsourced via Bio101) |
Clinical Advisory Board | Includes Dr Salvatore Fiorenza (Lead Investigator) and Prof. Cameron Turtle (appointed FY2026); full membership not enumerated in sources reviewed |
Scientific founder / adviser | Prof. Anastasios Karadimitris (Imperial College London), originally appointed via Imperial Consultants as Chair of the Scientific Advisory Board (FY2022) |
Outsourced partners | CTPL (manufacturing); SAPRO (CRO); HLB Mann Judd (audit); Automic (registry) |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD Mn) | 0.296 | 0.406 | 0.017 | 0.136 | 0 |
Other income – R&D Tax Incentive (AUD Mn) | — | — | — | 3.303 | 3.498 |
Interest income (AUD Mn) | — | — | — | 0.390 | 0.800 |
Research costs (AUD Mn) | — | — | — | 6.522 | 5.873 |
Employee benefits expense (AUD Mn) | — | — | — | 2.215 | 2.785 |
Share-based payment expense (AUD Mn) | — | — | — | 0.845 | 0.482 |
Other expenses (AUD Mn) | — | — | — | 1.650 | 1.956 |
Depreciation and amortisation (AUD Mn) | — | — | — | 0.107 | 0.118 |
Operating loss excl. interest income (AUD Mn) | — | — | — | -7.899 | -7.716 |
EBITDA (derived; AUD Mn) | — | — | — | -7.792 | -7.598 |
Pre-tax loss (AUD Mn) | -8.621 | -10.181 | -8.746 | -7.509 | -6.916 |
Income tax expense (AUD Mn) | — | — | — | 0 | 0 |
Net loss (AUD Mn) | -8.621 | -10.181 | -8.746 | -7.509 | -6.916 |
Basic EPS (AUD cents) | — | — | — | -0.68 | -0.58 |
Diluted EPS (AUD cents) | — | — | — | -0.68 | -0.58 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (m) | — | — | — | 1,097.2 | 1,201.1 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 6.071 | 5.175 | 12.714 | 20.877 | 14.353 |
Other current assets (AUD Mn) | — | — | — | 0.293 | 0.304 |
Total current assets (AUD Mn) | — | — | — | 21.170 | 14.657 |
Property, plant and equipment (AUD Mn) | — | — | 0.131 | 0.431 | 0.352 |
Total assets (AUD Mn) | — | — | — | 21.600 | 15.010 |
Trade and other payables (AUD Mn) | — | — | — | 1.361 | 0.718 |
Total liabilities (AUD Mn) | — | — | — | 1.524 | 0.857 |
Short-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt (AUD Mn; negative = net cash) | -6.071 | -5.175 | -12.714 | -20.877 | -14.353 |
Total equity (AUD Mn) | — | — | 11.228 | 20.076 | 14.152 |
Goodwill and intangibles (AUD Mn) | — | — | — | 0 | 0 |
Working capital (AUD Mn) | — | — | — | 19.677 | 13.820 |
Issued capital (AUD Mn) | — | — | 104.296 | 120.128 | 121.270 |
Accumulated losses (AUD Mn) | — | — | -95.506 | -102.837 | -108.622 |
Net tangible assets per share (AUD cents) | — | — | — | 1.69 | 1.17 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Payments to suppliers and employees (AUD Mn) | — | — | — | -10.623 | -11.204 |
R&D tax incentive and grants received (AUD Mn) | — | — | — | 3.303 | 3.498 |
Interest received (AUD Mn) | — | — | — | 0.390 | 0.800 |
Operating cash flow (AUD Mn) | — | — | — | -6.930 | -6.906 |
Capex – PP&E (AUD Mn) | — | — | — | -0.413 | -0.039 |
Free cash flow (AUD Mn) | — | — | — | -7.343 | -6.945 |
Equity proceeds, gross (AUD Mn) | — | — | — | 16.810 | 0.507 |
Share issue costs (AUD Mn) | — | — | — | -1.288 | -0.018 |
Net financing cash flow (AUD Mn) | — | — | — | 15.522 | 0.489 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD Mn) | — | — | — | 8.160 | -6.458 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (%; net loss / average equity) | -48.0 | -40.4 |
ROA (%; net loss / average total assets) | — | -37.8 |
Current ratio (x) | 14.18 | 17.51 |
Debt / equity (x) | 0 | 0 |
Asset turnover (x; revenue / average assets) | — | 0 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue – all regions, split not disclosed (AUD Mn) | 0.017 | 0.136 | 0 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.023 | 0.050 | 0.140 | 0.100 | 0.062 |
Market capitalisation at 30 June (AUD Mn) | 15.41 | 42.50 | 147.08 | 118.86 | 74.95 |
Shares on issue at 30 June (m) | — | — | 1,050.6 | 1,188.6 | 1,208.9 |
Share Price & Returns
| Horizon | Return | Basis |
|---|---|---|
1-year | About -40% (Stockopedia, as of early Oct 2026); Market Index shows -46.9% relative to the ASX 200 | Aggregators |
3-year | About -6% (A$0.050 at 30 Jun 2023 to about A$0.047 on 7 Oct 2026) | Analyst calculation from company and Investing.com data |
5-year | About -18% (A$0.057 at 30 Jun 2021 to about A$0.047) | Market Index year-end data; analyst calculation |
52-week range | A$0.046 – A$0.103 | Investing.com (7 Oct 2026) |
Peak (fiscal year-end) | A$0.140 (30 Jun 2024); intra-period high about A$0.18–0.185 (late 2024) | Company; Market Index director-transaction prices |
Valuation Multiples
| Multiple | Arovella | Comment |
|---|---|---|
Market capitalisation | A$56.8m | 1,208.85m shares |
Enterprise value | About A$42.5m | Market cap less 30 Jun 2026 cash of A$14.35m; overstated once Q1 FY2027 burn is deducted |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | Nil revenue |
P/B | 4.0x | Book equity A$14.15m |
Price / net cash | 4.0x | GuruFocus cited 3.0–3.6x at earlier prices |
Capital Instruments
| Instrument | Number | Exercise price (AUD) | Expiry |
|---|---|---|---|
Ordinary shares | 1,208,851,853 | — | — |
Placement-attaching options | 155,803,175 | 0.150 | 24 May 2027 |
Employee/director options (various) | 34,240,812 | 0.031–0.279 | Dec 2026 – Oct 2030 |
Total options | 190,043,987 | WAEP 0.136 | — |
Analyst Conclusions
Management guidance
-
First-patient dosing of ALA-101 by late October 2026 at The Alfred.
-
Activation of additional Australian and New Zealand sites.
-
Preliminary clinical data (safety and B-cell depletion) in early CY2027.
-
Continued ALA-105 in vivo proof-of-concept and evaluation of autoimmune indications.
-
No financial guidance.
Consensus expectations
There is no meaningful consensus revenue or EPS forecast. The FY2027 loss is likely to exceed FY2026's A$6.9m as clinical costs scale. That is an analyst view, not guidance.
Bull case
-
Valuation asymmetry. EV is about A$42m for a CAR-iNKT platform with an FDA-cleared process, GMP material released and a trial open. Clean safety and evidence of cell expansion or B-cell depletion in the first dose cohorts could plausibly re-rate the stock towards the A$118–147m market caps reached in FY2024–FY2025.
-
Autoimmune optionality at no extra product cost. The Phase 1 measures CD19 B-cell depletion directly. A positive pharmacodynamic signal would open the best-funded segment of the cell-therapy market without a new IND-enabling package.
-
Business-development-oriented board. The new directors bring licensing (Diamond), regulatory and development (Thurn) and capital-markets/M&A (Williams) experience. That raises the odds of a regional licence, an in-licence from Baylor, or a corporate transaction that crystallises value.
Bear case
-
Financing overhang. Cash of A$14.35m against roughly A$7m of net annual burn before trial escalation means a raise is likely before or shortly after the first data, at prices near A$0.05. With 190m options mostly out of the money, the registry has been carrying losses since 2024 and dilution could be heavy.
-
Execution and leadership risk. An acting CEO, a three-person board, eight director changes and two shareholder requisitions in one year, plus a one-month dosing slip, raise concern that strategic churn could distract from execution of a first-in-human trial.
-
Modality and competitive risk. CAR-iNKT persistence in humans is unproven at scale. Even with clean safety, efficacy must stand against approved autologous CD19 CAR-Ts, bispecifics, and better-funded allogeneic and autoimmune competitors (Allogene, Caribou, Cabaletta, Kyverna, Nkarta).
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | First patient dosed with ALA-101 |
| 30 Oct 2026 | AGM: director elections, remuneration report vote, possible new LTI grants |
| By 31 Oct 2026 | September-quarter 4C: cash balance and burn trajectory |
| Q4 CY2026 – Q1 CY2027 | Additional ANZ site activations; enrolment pace in dose escalation |
| Q4 CY2026 – H1 CY2027 | Permanent CEO appointment, or confirmation of van der Weerden |
| Early CY2027 | Preliminary safety, PK and B-cell-depletion data from first cohorts |
| H1 CY2027 | Capital raise (size, price, structure) |
| CY2027 | ALA-105 in vivo proof-of-concept readout; IND-enabling decision |
| CY2027 | Autoimmune indication selection (e.g. SPS) and regulatory pathway |
| Any time | Baylor in-licence or other business-development transaction |
| 24 May 2027 | Expiry of 155.8m A$0.15 options (overhang removal) |
| Ongoing | R&D Tax Incentive refund for FY2026 (about A$3.5m expected, in line with FY2025–FY2026) |
Analyst verdict
Arovella Therapeutics is a textbook example of an asymmetric, event-driven micro-cap biotech. On the evidence of its filings, the operating build is better than the share price suggests. Over 18 months the company filed and cleared a US IND, secured TGA and ethics approvals, manufactured and released GMP clinical material, and opened a reputable lead site. That is real progress for a company spending about A$7m a year net of the R&D Tax Incentive, and it rests on one of the very few CAR-iNKT platforms globally.
The market is nevertheless pricing the company at about A$42m of enterprise value, near its 52-week low. Three overlays explain this. The first is financing: cash of A$14.35m and an inevitable raise before meaningful data. The second is governance: a CEO exit forced by a requisition, an acting chief executive, a three-person board with negligible shareholdings, and option-based incentives without performance hurdles. The third is modality: there is no human CAR-iNKT persistence data yet, in a CD19 market crowded with approved and late-stage alternatives. The October 2026 dosing slip is small in isolation, but it reinforces the execution discount.
The investment case therefore turns on a short sequence. Arovella needs to dose cleanly, show safety, and show measurable cell expansion and B-cell depletion in early CY2027. If it does, the autoimmune and solid-tumour options gain credibility, the new board's business-development experience becomes valuable, and recapitalisation can happen at materially higher prices. If early cohorts show poor persistence or unexpected toxicity, the platform thesis weakens sharply and the equity becomes a cash-plus-licences option heading for heavy dilution.
Verdict: Speculative, high-risk, catalyst-driven. Monitor first-patient dosing, the September-quarter 4C, permanent CEO appointment and early-2027 pharmacodynamic data. A raise priced before data would be a clear negative signal; partnership-linked or post-data funding would be a positive one.
APPENDIX A — DATA DISCREPANCIES AND VERIFICATION FLAGS
| Item | Discrepancy / flag |
|---|---|
| Ticker / website in input list | SUD.AX and sudapharma.com are obsolete; current identifiers are ALA and arovella.com |
| Name-change date | Market Index records SUDA Pharmaceuticals until 22 Oct 2021; Yahoo/S&P says October 2021 (consistent) |
| HQ location | Some aggregators (Motley Fool/Morningstar, stoxray) still list Osborne Park, WA; the FY2026 Annual Report lists Preston, VIC |
| Employee count | GuruFocus 44 vs Kalkine 0; not disclosed by the company |
| Current share price | Investing.com A$0.047 (7 Oct 2026) vs Yahoo A$0.060; Investing.com used |
| Market Index status label | Page displayed a "HALTED SUSPENDED" label in October 2026; no supporting trading-halt announcement was located and Investing.com shows normal trading on 7 Oct 2026. |
| Substantial holders | Morningstar top-20 shows two holders above 5%; Market Index's substantial-holder database shows none lodged |
| Requisitioner identity | Not disclosed in the ASX releases reviewed |
| Interim chair Feb–Apr 2026 | — |
| FY2022–FY2024 detailed financials | Only revenue, net loss, year-end price and market cap verified from primary source; FY2022–FY2023 cash from aggregator |
| ALA-104 (DKK1) status | Not disclosed; absent from current pipeline descriptions |
| Quartr event labels | Some Quartr summaries are mislabelled by period (e.g. a "Q3 2026 TU" summary describes FY2025 metrics); primary filings used instead |
APPENDIX B — PRINCIPAL SOURCES
-
Arovella Therapeutics, Appendix 4E and Annual Report for the year ended 30 June 2026 (20 Aug 2026): https://investorpa.com/announcement-pdf/20260820/330312.pdf
-
ASX release, IND accepted by US FDA (29 Jan 2026): https://announcements.asx.com.au/asxpdf/20260129/pdf/06vph0kh8b86js.pdf
-
ASX release, Update regarding s249D notice (22 Apr 2026): https://announcements.asx.com.au/asxpdf/20260422/pdf/06yr2prk08cv8n.pdf
-
ASX release, s249D notice withdrawn (23 Apr 2026): https://announcements.asx.com.au/asxpdf/20260423/pdf/06ys0zqsmfl71k.pdf
-
ASX release, Board refresh and CEO resignation (4 May 2026): https://announcements.asx.com.au/asxpdf/20260504/pdf/06z6dj7cbtnf57.pdf
-
ASX release, Ethics approval for first-in-human trial (25 Jun 2026): https://announcements.asx.com.au/asxpdf/20260625/pdf/070zn2gz8fgh6p.pdf
-
ASX release, Clinical batch released and first site activated (7 Sep 2026): https://announcements.asx.com.au/asxpdf/20260907/pdf/073sqn98tzslyg.pdf
-
Kalkine summary of 1 Oct 2026 filing (dosing guided to late October): https://kalkinemedia.com/au/news/announcements/arovella-therapeutics-initiates-patient-screening-for-phase-1-ala-101-trial-with-first-dosing-slated-for-october-2026
-
Arovella website news pages (SAPRO CRO, CEO letter, Prenzler coverage): https://www.arovella.com
-
FilingReader summaries of Q4 FY2026 4C and FY2026 results: https://filingreader.com
-
Quartr event summaries (Q2 FY2026 4C; corporate presentations): https://quartr.com/companies/arovella-therapeutics-limited_18273
-
Market Index company page (former names, listing date, top 20, director transactions): https://www.marketindex.com.au/asx/ala
-
Investing.com price page (7 Oct 2026): https://au.investing.com/equities/suda-ltd
-
Stockopedia (1-year return; consensus target): https://www.stockopedia.com/share-prices/arovella-therapeutics-ASX:ALA/
-
GuruFocus (ISIN; events): https://www.gurufocus.com/stock/ASX:ALA/summary
-
Biotech Dispatch (2025 placement default and replacement; IND coverage): https://biotechdispatch.com.au
-
Clinical Trials Arena (March 2024 A$12.5m placement): https://www.clinicaltrialsarena.com/news/arovella-non-hodgkins-lymphoma-trial/
-
TipRanks (A$15m placement completion; option quotation): https://www.tipranks.com/news/company-announcements/arovella-therapeutics-secures-15-million-through-share-placement
-
CTPL release (manufacturing partner; pipeline references): https://celltherapies.com/arovella-ind-acceptance-for-inkt-cell-therapy-platform/
-
Arovella FY2022 Annual Report and Appendix 4E (Imperial licence 18 Jun 2021; DKK1 licence; STADA): https://www.asx.com.au/asxpdf/20220831/pdf/45dkgk1bj7ydjd.pdf
-
Edison Investment Research notes on SUDA/Arovella (2021–2022): https://www.edisongroup.com/equity/arovella-therapeutics/
-
SUDA/Teva ZolpiMist licence (2017): https://wholesaleinvestor.com.au/suda-pharmaceuticals-signs-licence-supply-deals-for-zolpimist-feasibility-option-agreement-with-pfizer/
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background / prior roles | Education | Shareholding |
|---|---|---|---|---|---|
Mr David Williams | Non-Executive Chair (Chair from 4 May 2026) | 28 Apr 2026 | Long career in ASX capital markets, business development and M&A; associated with Kidder Williams (corporate advisory) | B.Com (Hons) and M.Econ (La Trobe); PhD research in finance (Univ. of Sydney); FAICD | 200,000 shares (indirect, via Lawn Views Pty Ltd ATF Angela Williams Family Trust; on-market purchase 9 Jun 2026 at A$0.067) |
Mr Mark Diamond | Non-Executive Director | 28 Apr 2026 | Former CEO, Antisense Therapeutics (now Percheron Therapeutics, ASX: PER); Biotech Advisor to Spark Plus and Locust Walk; record in licensing deals and partnerships | BSc (Monash); MBA (Macquarie) | Nil |
Dr Michael Thurn | Non-Executive Director | 28 Apr 2026 | More than 25 years in biotech. Former MD/CEO of Neurizon Therapeutics (ASX: NUZ, formerly PharmAust); co-founder and Executive Director of MARP Therapeutics; COO and Executive Director of Botanix Pharmaceuticals; CEO of Mimetica and Spinifex Pharmaceuticals; former TGA regulatory reviewer | BAppSc (Hons) and PhD (UTS) | Nil |
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Dr Nicole van der Weerden | Acting Chief Executive Officer | Acting CEO since May 2026; previously Chief Operating Officer | BSc, BSc (Hons), PhD, MBA (Melbourne Business School) per Yahoo profile; three-month notice period |
Mr Lachie Mallia | CFO and Company Secretary | Since 22 Jan 2026 | Director of Bio101 (outsourced CFO, company-secretarial and transaction advisory services to healthcare); Chartered Accountant |
Tony Macintyre | GM and CTO (per Yahoo profile) | — | Not disclosed; current status not confirmed in FY2026 Annual Report |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Cash salary/fees | Bonus | Non-monetary | Super | LSL | Options (SBP) | Total |
|---|---|---|---|---|---|---|---|
Michael Baker (MD/CEO; resigned 4 May 2026) | 420,109 | 95,156 | 47,143 | 30,000 | 0 | -32,120 | 560,288 |
Nicole van der Weerden (Acting CEO) | 342,516 | 54,429 | 13,976 | 30,000 | 1,181 | 61,859 | 503,961 |
Elizabeth Stoner (Interim Chair; resigned 9 Feb 2026) | 61,007 | 0 | 0 | 0 | 0 | 0 | 61,007 |
Debora Barton (NED; resigned 4 May 2026) | 54,683 | 0 | 0 | 0 | 0 | 0 | 54,683 |
Gary Phillips (NED; resigned 9 Feb 2026) | 39,658 | 0 | 0 | 0 | 0 | 34,031 | 73,689 |
Andrew Nash (NED; 12 Nov 2025–4 May 2026) | 31,030 | 0 | 0 | 0 | 0 | 0 | 31,030 |
Michael Perry (NED; 28 Apr–4 May 2026) | 1,241 | 0 | 0 | 0 | 0 | 0 | 1,241 |
David Williams (Chair) | 15,113 | 0 | 0 | 1,814 | 0 | 0 | 16,927 |
Mark Diamond (NED) | 10,156 | 0 | 0 | 1,219 | 0 | 0 | 11,375 |
Michael Thurn (NED) | 11,375 | 0 | 0 | 0 | 0 | 0 | 11,375 |
Total KMP | 986,888 | 149,585 | 61,119 | 63,033 | 1,181 | 63,770 | 1,325,576 |
Directors' Remuneration (Annual)
| KMP remuneration trend | FY2025 | FY2026 |
|---|---|---|
Total KMP compensation (AUD Mn) | 1.775 | 1.326 |
Share-based payments to KMP (AUD Mn) | 0.474 | 0.064 |
CEO total – Michael Baker (AUD Mn) | 0.774 | 0.560 |
Governance Overview
| Attribute | Status (post-May 2026) |
|---|---|
Board size | 3, all non-executive |
Independence | All three are non-executive. The FY2026 Annual Report does not formally confirm independence assessments. Given the requisition context, investors should check the Appendix 4G and Corporate Governance Statement on arovella.com |
Chair / CEO separation | Yes. The chair is non-executive and the CEO role is held on an acting basis by an executive who is not a director. Since Baker's resignation there is no managing director on the board |
Committees | A Risk & Audit Committee met once in FY2026 (members Baker, Stoner, Barton, Phillips, all since departed). Current committee composition is not disclosed; with three directors, committee functions are likely exercised by the full board |
FY2026 board meetings | 13 held. Baker, Barton 13/13; Nash 8/8; Stoner, Phillips 6/7; Williams, Diamond, Thurn 6/6; Perry 1/1 |
Gender diversity | Board currently 0% female (previously included Dr Stoner and Dr Barton) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Jul 2025 | Dr Thomas Duthy resigns as Non-Executive Chair | Dr Elizabeth Stoner becomes Interim Chair |
12 Nov 2025 | Dr Andrew Nash appointed NED | Board strengthening ahead of IND |
22 Jan 2026 | Tim Luscombe replaced by Lachie Mallia as CFO and Company Secretary | Outsourced finance model via Bio101 |
9 Feb 2026 | Stoner and Phillips resign | Chair vacancy; who chaired from February to April 2026 is not disclosed in sources reviewed |
8–23 Apr 2026 | Purported s249D requisition to appoint three directors; ruled invalid by the board; withdrawn | Requisitioner identity not disclosed in sources reviewed; nominees declined to meet the board |
28 Apr 2026 | Williams, Diamond, Thurn and Perry appointed | Company disclosures do not say whether these were the requisitioner's nominees |
4 May 2026 | Second s249D notice seeks removal of Baker and Perry; Baker, Nash, Barton and Perry resign; Williams becomes Chair | Board launches strategic review of platform, strategy and growth |
May 2026 | van der Weerden made Acting CEO | No permanent CEO search outcome disclosed as of October 2026 |
Major Shareholders
| Rank | Holder | Shares | % of capital |
|---|---|---|---|
| 1 | Biotech Capital Management | 129,606,597 | 10.72 |
| 2 | Richard John Mann | 68,487,674 | 5.67 |
| 3 | Netwealth Investments – Wrap Services A/C | 33,595,541 | 2.78 |
| 4 | Netwealth Investments – Super Services A/C | 32,619,851 | 2.70 |
| 5 | Ajava Holdings Pty Ltd | 30,000,000 | 2.48 |
| 6 | UBS Nominees Pty Ltd | 29,070,196 | 2.40 |
| 7 | Blackburne Capital Pty Ltd | 27,268,039 | 2.26 |
| 8 | Legacy Asset Holdings Pty Ltd | 22,362,889 | 1.85 |
| 9 | Dylide Pty Ltd | 16,227,481 | 1.34 |
| 10 | M & M Stock One Pty Ltd | 15,958,668 | 1.32 |
Competitive Landscape
Key Competitors
| Competitor | Listing | Modality / asset | Overlap with Arovella | Relative positioning |
|---|---|---|---|---|
MiNK Therapeutics | Nasdaq: INKT | Allogeneic iNKT cells (agenT-797), unengineered and CAR-engineered | Closest iNKT pure-play | Further advanced clinically in iNKT (multiple trials), but cash-constrained; validates the modality |
Kuur Therapeutics (formerly in Athenex) | Private / asset status uncertain after Athenex bankruptcy (2023) | CAR-iNKT (Baylor-derived; CD19 and GD2 programmes) | Direct CAR-iNKT precedent; Baylor link | Demonstrated the CAR-iNKT concept clinically; corporate disruption reduced competitive threat |
Allogene Therapeutics | Nasdaq: ALLO | Allogeneic CAR-T (cema-cel, CD19) | Off-the-shelf CD19 cell therapy in lymphoma | Much better capitalised; pivotal-stage allogeneic CAR-T |
Caribou Biosciences | Nasdaq: CRBU | CRISPR-edited allogeneic CAR-T (CD19) | Off-the-shelf CD19 | Clinical data in LBCL; gene-editing approach to GvHD |
Fate Therapeutics | Nasdaq: FATE | iPSC-derived NK/T cell therapies, incl. autoimmune | Off-the-shelf innate-cell platform; autoimmune pivot | Larger platform; iPSC manufacturing |
Nkarta | Nasdaq: NKTX | Allogeneic CAR-NK (CD19), autoimmune focus | Innate-cell CD19 for autoimmune | Direct competitor for the autoimmune B-cell-depletion thesis |
Cabaletta Bio | Nasdaq: CABA | Autologous CD19 CAR-T for autoimmune disease | CD19 autoimmune | Leading autoimmune CAR-T developer |
Kyverna Therapeutics | Nasdaq: KYTX | Autologous CD19 CAR-T (KYV-101), incl. stiff-person syndrome | Directly overlaps the SPS example | Ahead clinically in SPS; sets the efficacy bar |
Kite (Gilead) / Novartis / BMS / Autolus | Large-cap; Autolus Nasdaq: AUTL | Approved autologous CD19 CAR-T (Yescarta, Tecartus; Kymriah; Breyanzi; Aucatzyl) | Standard of care Arovella must improve on in access, cost and toxicity | Commercial incumbents |
Imugene | ASX: IMU | Allogeneic CD19 CAR-T (azer-cel) | ASX-listed allogeneic CD19 peer | Closest ASX comparator; already reporting clinical data |
Chimeric Therapeutics | ASX: CHM | CAR-T/CAR-NK (CLTX, CDH17) | ASX cell-therapy peer; solid tumours | Small-cap peer, also capital-constrained |
CARsgen Therapeutics | HKEX: 2171 | CLDN18.2 CAR-T (satri-cel) | Directly overlaps ALA-105 target | Late-stage in China; target validation and competitive bar |
Astellas | TSE: 4503 | Zolbetuximab (CLDN18.2 mAb, approved 2024) | CLDN18.2 gastric standard of care | Defines the CLDN18.2 treatment landscape |
Peer Comparison FY2026
| Metric | Arovella (ALA) | MiNK Therapeutics (INKT) | Imugene (IMU) | Allogene (ALLO) |
|---|---|---|---|---|
Modality | Allogeneic CAR-iNKT | Allogeneic iNKT | Allogeneic CD19 CAR-T plus oncolytics | Allogeneic CAR-T |
Most advanced stage | Phase 1 (dosing pending) | Phase 1/2 | Phase 1b | Pivotal Phase 2 |
Latest annual revenue | 0 (FY2026, AUD) | — | — | — |
Revenue growth | n/m | — | — | — |
Margins | n/m | n/m (pre-revenue) | n/m | n/m |
R&D intensity | Research costs 52% of opex (FY2026) | — | — | — |
Cash (latest) | A$14.35m (30 Jun 2026) | — | — | — |
Recent Developments
There have been no material litigation, guidance revisions of financial nature, or layoffs disclosed in the period.



